Ansa Raises 71 5 Million to Scale Long DNA Synthesis

Company Ansa Biotechnologies Event Type Series C financing ($71.5 million) Modality Enzymatic long DNA synthesis Asset Sequence-perfect clonal DNA up to 50 kb Target Not applicable (supply infrastructure) Disease Area Platform tool for cell and gene therapy, vaccines and research Summary Ansa Biotechnologies announced a…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *